James P. Quinlan
Known title: Chief Financial OfficerCIK: 0002047493
Associated companies
Transaction History
| MDCX | ▲ Buy | Option Exercise | 125,000 | $101K | 8/13/2025 | View on chart |
| MDCX | ▲ Buy | Option Exercise | 20,000 | $55K | 8/13/2025 | View on chart |
| MDCX | ▲ Buy | Option Exercise | 125,000 | $101K | 8/13/2025 | View on chart |
| MDCX | ▲ Buy | Option Exercise | 20,000 | $55K | 8/13/2025 | View on chart |
We use analytics to understand how market-wall is used. No personal data is sold.
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 1, 2026
Medicus Pharma Files Optimized Phase 2b/3 Protocols for Teverelix
Medicus Pharma has filed a streamlined Phase 2b/3 trial design and an optimized registrational protocol for its Teverelix product with the FDA. The filings are aimed at creating a partner‑ready program for advanced prostate cancer treatment. These submissions represent a development milestone that could affect the company’s future regulatory outlook.
Medicus Pharma Files Optimized Phase 2b/3 Protocols for Teverelix. Medicus Pharma has filed a streamlined Phase 2b/3 trial design and an optimized registrational protocol for its Teverelix product with the FDA. The filings are aimed at creating a partner‑ready program for advanced prostate cancer treatment. These submissions represent a development milestone that could affect the company’s future regulatory outlook.